Comparative Pharmacology
Head-to-head clinical analysis: LUFYLLIN versus SLO BID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUFYLLIN versus SLO BID.
LUFYLLIN vs SLO-BID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.
Relaxes smooth muscle of bronchial airways and pulmonary blood vessels by inhibiting phosphodiesterase, increasing intracellular cAMP, and promoting bronchodilation.
200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/mL injection, administer 200-400 mg IM or slow IV every 6-8 hours.
Dose: 300-600 mg orally every 12 hours. Immediate-release: 5 mg/kg loading dose then 3 mg/kg every 6 hours. Extended-release: 10-15 mg/kg/day divided every 12 hours. Titrate to serum theophylline concentration of 5-15 mcg/mL.
None Documented
None Documented
6-8 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged to 20-30 hours. In patients with hepatic cirrhosis, half-life may extend to 20-30 hours. In congestive heart failure, half-life is prolonged to 12-20 hours.
Terminal elimination half-life: 3-15 hours (mean ~10 hours in adults; 20-30 hours in neonates; 1-5 hours in smokers). Clinically, half-life decreases with smoking, increases with hepatic disease, heart failure, and certain drugs (e.g., cimetidine, ciprofloxacin).
Primarily renal excretion of unchanged drug and metabolites. Approximately 50% is excreted unchanged in urine, with the remainder as metabolites (including 7-hydroxypropyltheophylline and 1,3-dimethyluric acid). Biliary/fecal elimination accounts for <10%.
Renal: 90% as metabolites (caffeine, theobromine, paraxanthine, and unchanged drug; 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine). Biliary/fecal: <10%.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator